TRANSDERMAL CANNABINOID PATCH
The present invention includes a transdermal patch which contains a pharmaceutically effective amount of a cannabinoid for delivery of the cannabinoid to the bloodstream of a user. The patch may comprise the following components: a backing; and a skin-adhesive polymer matrix attached to one side of the backing, which includes a cannabinoid, a carrier agent, a terpene, and a permeation agent. The cannabinoid is capable of diffusing from the matrix in the transdermal patch into the bloodstream of the user, and may be used in methods for treating a patient suffering from a condition such as pain, nausea and emesis, convulsions, muscle spasm, inflammation, depression, and cachexia.
1 . A transdermal patch comprising a pharmaceutically effective amount of a cannabinoid for delivery of the cannabinoid to the bloodstream of a user, said patch comprising:
a) a backing
b) a skin-adhesive polymer matrix attached to one side of the backing, said matrix comprising a cannabinoid, a carrier agent, an exogenous terpene, and a permeation agent;
wherein the cannabinoid is capable of diffusing from the matrix in the transdermal patch into the bloodstream of the user.
2 . The patch of claim 1 , wherein the permeation agent comprises a methylsulfoxide.
3 . The patch of claim 2 , wherein the permeation agent comprises dodecylmethylsulfoxide.
4 . The patch of claim 3 , wherein the dodecylmethylsulfoxide is in the amount of between about 0.5% and about 1.5% w/w.
5 . The patch of claim 1 , wherein the carrier agent comprises a long chain fatty acid.
6 . The patch of claim 5 , wherein the long chain fatty acid is oleic acid.
7 . The patch of claim 6 , wherein the carrier agent is in the amount between about 7% and about 12%.
8 . The patch of claim 1 , wherein the terpene is eucalyptol.
9 . The patch of claim 8 , where the eucalyptol is in the amount of between about 0.3% and about 0.7%.
10 . The patch of claim 1 , wherein the cannabinoid comprises THC.
11 . The patch of claim 10 , wherein the THC is in an amount between about 7% and about 12%.
12 . The patch of claim 1 , wherein the cannabinoid comprises THCa.
13 . The patch of claim 10 , wherein the THCa is in an amount between about 7% and about 12% w/w.
14 . The patch of claim 1 , wherein the cannabinoid comprises CBD.
15 . The patch of claim 1 , wherein the CBD is in an amount between about 7% and about 12% w/w.
16 . The patch of claim 1 , wherein the cannabinoid comprises CBDa.
17 . The patch of claim 10 , wherein the CBDa is in an amount between about 7% and about 12% w/w.
18 . The patch of claim 1 , wherein the cannabinoid comprises CBN in an amount of between about 7% and 12% w/w.
19 . The patch of claim 1 , wherein the cannabinoid comprises CBC in an amount of between about 7% and 12% w/w.
20 . The patch of claim 1 , wherein the cannabinoid comprises HTCv in an amount of between about 7% and 12% w/w.
21 . The patch of claim 1 , wherein the cannabinoid comprises CBC in an amount of between about 7% and 12% w/w.
22 . The patch of claim 1 , wherein the patch further comprises a release liner, said release liner being removably attached to said polymer matrix.
23 . A method for treating a patient suffering from a condition selected from the group consisting of pain, nausea and emesis, convulsions, muscle spasm, inflammation, depression, and cachexia comprising administering the patch of claim 1 .